Akari Therapeutics Files PCT for ADC Payload
Akari Therapeutics has filed a PCT for its PH1 payload, which is designed to disrupt cancer-driving pathways and has a cytotoxic mechanism. This filing expands the company's intellectual property portfolio for its novel payload and ADC platform.